Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | BRD2 | P25440 | 3/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 11/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 11/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 11/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18871818 | 0.83 | CD274 (0.42) | BRD4BRD2BRD3PDK1PDK2 | |
| SCHEMBL30366640 | 0.81 | ALDH1A1 (0.46) | BRD4BRD2BRD3PDK1PDK2 | |
| SCHEMBL27265643 | 0.81 | CD274 (0.40) | BRD4BRD2BRD3PDK1PDK2 | |
| SCHEMBL26079016 | 0.80 | WDR5 (0.45) | BRD4BRD2BRD3PDK1PDK2 | |
| SCHEMBL18871766 | 0.79 | LMNA (0.39) | BRD4BRD2BRD3PDK1PDK2 | |
| SCHEMBL26079727 | 0.79 | KMT2A (0.42) | BRD4BRD2BRD3PDK1PDK2 | |
| SCHEMBL26079791 | 0.77 | ALDH1A1 (0.44) | BRD4PDK1PDK2PDK3PDK4 | |
| SCHEMBL14756175 | 0.76 | BRD4 (0.56) | BRD4BRD2BRD3PDK1PDK2 | |
| SCHEMBL30366353 | 0.76 | PDK1 (0.48) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL26071914 | 0.76 | CYP11B1 (0.47) | BRD4BRD2BRD3PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| EP-4165045-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | Monash University (AU) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | BRD4 10/4885BRD2 8/4885BRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.